文献速递神经重症神经肿瘤脑血管病外科

神经重症患者肠内格列本脲低血糖风险因素分析

Risk Factors for Hypoglycemia with the Use of Enteral Glyburide in Neurocritical Care Patients.
PubMed 文献 · World Neurosurg · 2020-11-27

多因素分析显示入院血清肌酐升高是低血糖的危险因素,而体重指数>30具有保护作用。

要点

  • 肠内格列本脲在神经重症患者中低血糖发生率较高,达23.9%。
  • 入院血清肌酐升高与低血糖风险增加独立相关。
  • 体重指数>30与低血糖风险降低独立相关。

核心结论

  • 神经重症患者使用肠内格列本脲后低血糖常见,无论是否合并糖尿病均存在风险。
  • 入院血清肌酐升高可能增加使用格列本脲预防或治疗脑或脊髓水肿时的低血糖风险。

研究设计与样本

  • 回顾性病例对照病历审查,比较发生低血糖与未发生低血糖的成人患者。

主要发现

  • 17例(23.9%)患者发生低血糖,定义为血糖<55.8 mg/dL。
  • 多数患者接受肠内格列本脲2.5 mg每日两次。
  • 诊断包括肿瘤(35.2%)、脑出血(28.2%)、脊柱术后(12.7%)和缺血性卒中(12.7%)。
  • 多因素分析显示入院血清肌酐为低血糖危险因素(比值比27.2,[1.661, 445.3],P<0.05)。
  • 体重指数>30为低血糖保护因素(比值比0.085,[0.008, 0.921],P<0.05)。

临床怎么用

  • 神经重症患者使用肠内格列本脲时需警惕低血糖,尤其入院血清肌酐升高者。
  • 对体重指数>30的患者低血糖风险可能较低,但仍需监测血糖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intravenous glyburide has demonstrated safety when used for attenuation of cerebral edema, although safety data are lacking for enteral glyburide when used for this indication. We aimed to determine the prevalence of and risk factors for hypoglycemia in neurocritical care patients receiving enteral glyburide. METHODS: We performed a retrospective case-control chart review (hypoglycemia vs. no hypoglycemia) of adult patients who received enteral glyburide for prevention or treatment of cerebral or spinal cord edema. Hypoglycemia was defined as a blood glucose <55.8 mg/dL. Descriptive statistics were used, with multivariate analysis to measure the association of risk factors and outcomes. Logistic regression was applied to outcomes with an exposure. Potential confounders were evaluated using the t-test or the Wilcoxon rank-sum test for continuous variables, and the χ2 test or the Fisher exact test for categorical variables. RESULTS: Seventy-one patients (60.6% men, median age 60 years) were included. The majority received 2.5 mg of enteral glyburide twice daily. Diagnoses included tumors (35.2%), intracerebral hemorrhage (28.2%), postspinal surgery (12.7%), and ischemic stroke (12.7%). Hypoglycemia occurred in 17 (23.9%) patients. Multivariate analysis identified admission serum creatinine (odds ratio, 27.2; [1.661, 445.3]; P < 0.05) as a risk factor for hypoglycemia, whereas body mass index >30 (odds ratio, 0.085; [0.008, 0.921]; P < 0.05) was protective. CONCLUSIONS: Hypoglycemic episodes are common following enteral glyburide in neurocritical care patients. Both patients with and without diabetes mellitus are at risk of hypoglycemia. Elevated admission serum creatinine may increase the risk of hypoglycemia when utilizing glyburide for prevention or treatment of cerebral or spinal cord edema.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Armahizer MJ, Howard AK, Seung H, et al. Risk Factors for Hypoglycemia with the Use of Enteral Glyburide in Neurocritical Care Patients. World Neurosurg. 2020. PMID: 33253952. doi:10.1016/j.wneu.2020.11.107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。